This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RXII vs. FGEN, MRNS, GRCE, CVKD, ALLK, OKUR, KZR, GBIO, CALC, and CYCCShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include FibroGen (FGEN), Marinus Pharmaceuticals (MRNS), Grace Therapeutics (GRCE), Cadrenal Therapeutics (CVKD), Allakos (ALLK), OnKure Therapeutics (OKUR), Kezar Life Sciences (KZR), Generation Bio (GBIO), CalciMedica (CALC), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "medical" sector. RXi Pharmaceuticals vs. FibroGen Marinus Pharmaceuticals Grace Therapeutics Cadrenal Therapeutics Allakos OnKure Therapeutics Kezar Life Sciences Generation Bio CalciMedica Cyclacel Pharmaceuticals RXi Pharmaceuticals (NASDAQ:RXII) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk. Does the media prefer RXII or FGEN? In the previous week, FibroGen had 2 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 2 mentions for FibroGen and 0 mentions for RXi Pharmaceuticals. FibroGen's average media sentiment score of 0.43 beat RXi Pharmaceuticals' score of 0.00 indicating that FibroGen is being referred to more favorably in the news media. Company Overall Sentiment RXi Pharmaceuticals Neutral FibroGen Neutral Do institutionals & insiders believe in RXII or FGEN? 9.6% of RXi Pharmaceuticals shares are held by institutional investors. Comparatively, 72.7% of FibroGen shares are held by institutional investors. 1.0% of RXi Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer RXII or FGEN? FibroGen received 155 more outperform votes than RXi Pharmaceuticals when rated by MarketBeat users. However, 68.09% of users gave RXi Pharmaceuticals an outperform vote while only 58.81% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformRXi PharmaceuticalsOutperform Votes19268.09% Underperform Votes9031.91% FibroGenOutperform Votes34758.81% Underperform Votes24341.19% Which has preferable earnings & valuation, RXII or FGEN? RXi Pharmaceuticals has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRXi Pharmaceuticals$10K893.52-$12.45M-$4.20-0.49FibroGen$7.00M4.50-$284.23M-$0.10-3.11 Do analysts prefer RXII or FGEN? FibroGen has a consensus target price of $10.00, suggesting a potential upside of 3,112.34%. Given FibroGen's stronger consensus rating and higher possible upside, analysts plainly believe FibroGen is more favorable than RXi Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RXi Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, RXII or FGEN? RXi Pharmaceuticals has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Is RXII or FGEN more profitable? FibroGen has a net margin of -67.66% compared to RXi Pharmaceuticals' net margin of -4,990.20%. FibroGen's return on equity of 0.00% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RXi Pharmaceuticals-4,990.20% -412.15% -179.54% FibroGen -67.66%N/A -36.17% SummaryFibroGen beats RXi Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.94M$6.59B$5.41B$8.39BDividend YieldN/A2.64%5.28%4.17%P/E Ratio-0.498.6926.8519.76Price / Sales893.52237.35405.12134.19Price / CashN/A65.8538.2534.64Price / Book2.656.336.784.51Net Income-$12.45M$143.71M$3.23B$247.95M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.04+2.0%N/A+157.7%$8.94M$10,000.00-0.49N/AGap UpFGENFibroGen4.0923 of 5 stars$0.31+2.5%$10.00+3,088.8%-72.8%$31.69M$7.00M-0.25570Short Interest ↑MRNSMarinus Pharmaceuticals2.4721 of 5 stars$0.55-0.2%$4.79+771.6%-64.3%$30.32M$30.99M-0.22110GRCEGrace Therapeutics2.8693 of 5 stars$2.99+6.8%$12.00+301.3%N/A$30.32MN/A-2.58N/ACVKDCadrenal Therapeutics2.1205 of 5 stars$15.35-1.0%$32.00+108.5%N/A$30.19MN/A-2.304Short Interest ↑ALLKAllakos4.5994 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190Positive NewsOKUROnKure Therapeutics3.0939 of 5 stars$2.20+10.0%$32.33+1,369.7%N/A$29.72MN/A-0.18N/AGap DownKZRKezar Life Sciences4.5044 of 5 stars$4.03-1.0%$39.50+880.1%-39.5%$29.44M$7M-0.3160Positive NewsShort Interest ↓GBIOGeneration Bio3.3084 of 5 stars$0.40+5.4%$7.33+1,725.1%-87.3%$26.94M$24.56M-0.18150Short Interest ↑CALCCalciMedica2.0505 of 5 stars$1.86-7.0%$18.00+867.7%-68.9%$25.99MN/A-1.7230Short Interest ↑CYCCCyclacel Pharmaceuticals1.4409 of 5 stars$2.00flatN/A-95.1%$25.92M$43,000.00-0.2114Positive NewsUpcoming EarningsShort Interest ↓Gap Down Related Companies and Tools Related Companies FGEN Alternatives MRNS Alternatives GRCE Alternatives CVKD Alternatives ALLK Alternatives OKUR Alternatives KZR Alternatives GBIO Alternatives CALC Alternatives CYCC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXII) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXII Stock Free RXII Stock Alerts